In order to identify synthetic lethal partners of EZH2 that are specifically effective in BRCA1-deficient breast cancer, we used BRCA1-deficient and -proficient mammary tumor cell lines to perform a high-throughput drug screen in combination with GSK126. This evidence concerns the gene EZH2 and breast carcinoma.